Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.
Share
Why It Matters
A big bank's expert thinks Zenas BioPharma stock looks even better now. They raised their target price from $41 to $48 because they believe in the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.